Evaluating the TaqMan Jra -Genotyping Method for Rapidly Predicting the Presence of Anti-Jra Antibodies
- Author:
Yu-Kyung KOO
1
;
Soon Sung KWON
;
Eun Jung SUH
;
Na Hyeong KIM
;
Hyun Kyung KIM
;
Youn Keong CHO
;
Seung Jun CHOI
;
Sinyoung KIM
;
Kyung-A LEE
Author Information
- Publication Type:Original Article
- From:Annals of Laboratory Medicine 2024;44(5):418-425
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The Jr a antigen is a high-prevalence red blood cell (RBC) antigen. Reports on cases of fatal hemolytic disease of the fetus and newborn and acute hemolytic transfusion reactions suggest that antibodies against Jr a (anti-Jra ) have potential clinical significance.Identifying anti-Jra is challenging owing to a lack of commercially available antisera. We developed an alternative approach to rapidly predict the presence of anti-Jra using the TaqMan single-nucleotide polymorphism (SNP)-genotyping method.
Methods:Residual peripheral blood samples from 10 patients suspected of having the anti-Jr a were collected. Two samples with confirmed Jr(a–) RBCs and anti-Jra were used to validate the TaqMan genotyping assay by comparing the genotyping results with direct sequencing. The accuracy of the assay in predicting the presence of anti-Jra was verified through crossmatching with in-house Jr(a–) O+ RBCs.
Results:The TaqMan-genotyping method was validated with two Jr(a–) RBC- and anti-Jra -confirmed samples that showed concordant Jr a genotyping and direct sequencing results.Jra genotyping for the remaining samples and crossmatching the serum samples with inhouse Jr(a–) O+ RBCs showed consistent results.
Conclusions:We validated a rapid, simple, accurate, and cost-effective method for predicting the presence of anti-Jra using a TaqMan-based SNP-genotyping assay. Implementing this method in routine practice in clinical laboratories will assist in solving difficult problems regarding alloantibodies to high-prevalence RBC antigens and ultimately aid in providing safe and timely transfusions and proper patient care.
